{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:22Z","timestamp":1793329762369,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T00:00:00Z","timestamp":1177891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Women with a family history of breast cancer are commonly offered regular clinical or mammographic surveillance from age 30. Data on the efficacy of such programmes are limited. Clinical, pathological and outcome data were recorded on all breast and ovarian cancers diagnosed within familial breast cancer surveillance programmes at collaborating centers in Norway and the UK up to the end of 2005. These have been analyzed according to the mutation status of the affected women (<jats:italic>BRCA1<\/jats:italic>+ve, <jats:italic>BRCA2<\/jats:italic>+ve or mutation\u2010negative). Breast cancer was diagnosed in 442 patients subsequently followed for a total of 2095 years. Eighty\u2010nine (20%) had <jats:italic>BRCA1<\/jats:italic> mutations, 35 (8%) <jats:italic>BRCA2<\/jats:italic> mutations and in 318 (72%) no mutation could be detected (\u201cmut neg\u201d). Five\u2010year survival in <jats:italic>BRCA1<\/jats:italic> was 73% compared to 96% in <jats:italic>BRCA2<\/jats:italic> and 92% in mut neg (<jats:italic>p<\/jats:italic> = 0.000). Among <jats:italic>BRCA1<\/jats:italic> mutation\u2010carriers, 5\u2010year survival was 67% for cases diagnosed as carcinoma <jats:italic>in situ<\/jats:italic>, 84% for node\u2010negative invasive cancers and 58% for those with nodal involvement (<jats:italic>p<\/jats:italic> &gt; 0.05). For <jats:italic>BRCA2<\/jats:italic> mutation\u2010carriers the corresponding figures were 100, 100 and 90% (<jats:italic>p<\/jats:italic> &gt; 0.05), while for mut neg women they were 100, 97 and 71% (<jats:italic>p<\/jats:italic> = 0.03). Regular surveillance in women at increased familial risk of breast cancer is associated with a good outcome if they carry <jats:italic>BRCA2<\/jats:italic> mutations or no detectable mutation. Carriers of <jats:italic>BRCA1<\/jats:italic> mutations fare significantly worse, even when their tumors are diagnosed at an apparently early stage. The differences in outcome associated with different genetic causes of disease were associated with demonstrated differences in tumor biology. The findings demonstrate the outcome for genetically different breast cancers detected within a programme for early diagnosis and treatment, which is relevant to genetic counseling when women at risk have to chose between the options for preventing death from inherited breast cancer. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.22789","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T19:47:28Z","timestamp":1177962448000},"page":"1017-1020","source":"Crossref","is-referenced-by-count":84,"title":["Surveillance for familial breast cancer: Differences in outcome according to <i>BRCA<\/i> mutation status"],"prefix":"10.1002","volume":"121","author":[{"given":"Pal","family":"Moller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovise","family":"Maehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaran","family":"Apold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Lucassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,30]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"2093","volume-title":"Emery and Rimoin's principles and practice of medical genetics","author":"Steel CM","year":"2007"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.15.1138"},{"key":"e_1_2_6_5_2","first-page":"782","article-title":"The pathology of familial breast cancer: histological features of cancers in families not due to mutations in BRCA1 or BRCA2","volume":"6","author":"Lakhani SR","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07065-7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.924"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj095"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr658"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10641"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1155\/1999\/805420"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00075-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.bjc.6600840","article-title":"BRCA1 and BRCA2 mutations in Scotland and Northern Ireland","volume":"88","author":"Scottish\/Northern Irish BRCA1\/BRCA2 Consortium","year":"2002","journal-title":"Br J Cancer"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.023"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9288-7"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr748"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-005-2832-5"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008340723974"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705153362022"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.5.617"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9801800402"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.979"},{"key":"e_1_2_6_23_2","first-page":"13","article-title":"Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1\/2\u2010positive women: a decision analysis","volume":"6","author":"Grann VR","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.035"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020119"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012158"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.20.2374"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3524"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66481-1"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031759"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2007.01.006"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.22789","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:37:01Z","timestamp":1697438221000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.22789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/ijc.22789"],"URL":"https:\/\/doi.org\/10.1002\/ijc.22789","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,30]]}}}